FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension

OBJECTIVE: To compare the efficacy, serum drug concentrations, immunogenicity, and safety of FKB327 with the adalimumab reference product (RP) in combination with methotrexate in patients with moderate-to-severe, active rheumatoid arthritis (RA). METHODS: Patients were randomized 1:1 in a double-bli...

Descripción completa

Detalles Bibliográficos
Autores principales: Genovese, Mark C., Glover, Josephine, Greenwald, Maria, Porawska, Wieslawa, El Khouri, Elias Chalouhi, Dokoupilova, Eva, Vargas, Juan Ignacio, Stanislavchuk, Mykola, Kellner, Herbert, Baranova, Elena, Matsunaga, Nobuhito, Alten, Rieke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909638/
https://www.ncbi.nlm.nih.gov/pubmed/31831079
http://dx.doi.org/10.1186/s13075-019-2046-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909638/
https://www.ncbi.nlm.nih.gov/pubmed/31831079
http://dx.doi.org/10.1186/s13075-019-2046-0

Ejemplares similares